 Phase I clinical study for an investigational PIKA Polyinosinic-Polycytidylic Acid Based Adjuvant rabies vaccine comprising Inactivated and Purified Rabies Virus IPRV and the PIKA adjuvant. The primary objective of the study was to assess the clinical safety of the vaccine composition in healthy adult volunteers. The secondary objective was to evaluate the vaccines efficacy based on an accelerated vaccine regimen. 